Company intelligence / Profile preview

Ranedis Pharmaceuticals

United States

Ownership: Private
Development stage: Other

Overview

Ranedis Pharmaceuticals is an early-stage biotech company focused on developing therapies for rare and neglected diseases, particularly lysosomal storage disorders and central nervous system disorders. The company leverages an HDAC inhibitor technology licensed from the University of Notre Dame. Its lead program, RND-001, a small molecule targeting histone deacetylase for lysosomal storage and CNS diseases, is in collaboration with AMO Pharma.

Therapeutic areas: NeurologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

AMO Pharma (collaboration agreement for RND-001 development; AMO Pharma has exclusive option to acquire worldwide rights)

Beyond the preview

Go deeper on Ranedis Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ranedis Pharmaceuticals.

Explore the full profile